(1) Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia
(2) Institute for Multidisciplinary Research-IMSI, University of Belgrade, Kneza Višeslava 1, Belgrade, Serbia
* Corresponding author Emailfirstname.lastname@example.org
As the leading cause of cancer-related deaths, the non-small-cell lung cancer captures the attention of researchers with the desire to design new therapies. Molecular aetiology of non-small-cell lung cancer is related to mutations in epidermal growth factor receptor, member of HER/ErbB family of receptors. Non-small-cell lung cancer is not genetically unique, emerging from mutations in exons 19, 20 and 21. Currently, the most advanced and the most widely accepted therapy includes tyrosine kinase inhibitors erlotinib (Tarceva™) and gefitinib (Iressa™). This paper discusses the differential response to targeted therapy in non-small-cell lung carcinoma patients harbouring epidermal growth factor receptor mutations.
The crucial and still unsolved question is the examination of treatment response in patients harbouring different mutations. Procedures involve kits that simultaneously detect several mutation types. Through application of spectroscopic and chemometrics, it can be partially solved, but demand for research kits rather than simple diagnostic kits remains for better understanding of non-small-cell lung cancer.